Literature DB >> 25002120

MUC16: molecular analysis and its functional implications in benign and malignant conditions.

Dhanya Haridas1, Moorthy P Ponnusamy1, Seema Chugh1, Imayavaramban Lakshmanan1, Parthasarathy Seshacharyulu1, Surinder K Batra2.   

Abstract

MUC16 is a high-molecular-weight glycoprotein that is expressed by the various epithelial cell surfaces of the human body to protect the cell layer from a myriad of insults. It is the largest mucin known to date, with an ∼22,152 aa sequence. Structurally, MUC16 is characterized into 3 distinct domains: the amino terminal, the tandem repeat, and the carboxyl terminal domain, with each domain having unique attributes. The extracellular portion of MUC16 is shed into the bloodstream and serves as a biomarker for diagnosing and monitoring patients with cancer; however, its functional role in cancer is yet to be elucidated. Several factors contribute to this challenge, which include the large protein size; the extensive glycosylation that the protein undergoes, which confers functional heterogeneity; lack of specific antibodies that detect the unique domains of MUC16; and the existence of splicing variants. Despite these limitations, MUC16 has been established as a molecule of significant application in cancer. Hence, in this review, we discuss the various aspects of MUC16, which include its discovery, structure, and biological significance both in benign and malignant conditions with an attempt to dissect its functional relevance © FASEB.

Entities:  

Keywords:  MUC16; animal model; cancer; domain structure

Mesh:

Substances:

Year:  2014        PMID: 25002120     DOI: 10.1096/fj.14-257352

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  52 in total

Review 1.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

2.  MUC16 suppresses human and murine innate immune responses.

Authors:  Mildred Felder; Arvinder Kapur; Alexander L Rakhmilevich; Xiaoyi Qu; Paul M Sondel; Stephen D Gillies; Joseph Connor; Manish S Patankar
Journal:  Gynecol Oncol       Date:  2019-01-06       Impact factor: 5.482

Review 3.  Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta; Amos Lal; Muhammad Masab; Rashmika Potdar
Journal:  Med Oncol       Date:  2018-04-12       Impact factor: 3.064

4.  Predicting Circulating CA125 Levels among Healthy Premenopausal Women.

Authors:  Naoko Sasamoto; Ana Babic; Bernard A Rosner; Renée T Fortner; Allison F Vitonis; Hidemi Yamamoto; Raina N Fichorova; Anne Tjønneland; Louise Hansen; Kim Overvad; Marina Kvaskoff; Agnès Fournier; Francesca Romana Mancini; Heiner Boeing; Antonia Trichopoulou; Eleni Peppa; Anna Karakatsani; Domenico Palli; Valeria Pala; Amalia Mattiello; Rosario Tumino; Chiara C Grasso; N Charlotte Onland-Moret; Elisabete Weiderpass; J Ramón Quirós; Leila Lujan-Barroso; Miguel Rodríguez-Barranco; Sandra Colorado-Yohar; Aurelio Barricarte; Miren Dorronsoro; Annika Idahl; Eva Lundin; Hanna Sartor; Kay-Tee Khaw; Timothy J Key; David Muller; Elio Riboli; Marc J Gunter; Laure Dossus; Rudolf Kaaks; Daniel W Cramer; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-04-04       Impact factor: 4.254

5.  N-Glycosylation affects the stability and barrier function of the MUC16 mucin.

Authors:  Takazumi Taniguchi; Ashley M Woodward; Paula Magnelli; Nicole M McColgan; Sylvain Lehoux; Sarah Melissa P Jacobo; Jérôme Mauris; Pablo Argüeso
Journal:  J Biol Chem       Date:  2017-05-09       Impact factor: 5.157

Review 6.  Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.

Authors:  Tova M Bergsten; Joanna E Burdette; Matthew Dean
Journal:  Cancer Lett       Date:  2020-02-15       Impact factor: 8.679

Review 7.  Interaction of host and Staphylococcus aureus protease-system regulates virulence and pathogenicity.

Authors:  Vigyasa Singh; Ujjal Jyoti Phukan
Journal:  Med Microbiol Immunol       Date:  2018-11-27       Impact factor: 3.402

Review 8.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

9.  Prospects for gene-engineered T cell immunotherapy for solid cancers.

Authors:  Christopher A Klebanoff; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

10.  Human conjunctival goblet cells express the membrane associated mucin MUC16: Localization to mucin granules.

Authors:  Ilene K Gipson; Sandra Spurr-Michaud; Ann Tisdale
Journal:  Exp Eye Res       Date:  2015-12-28       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.